Brandon Scalea | Authors


Ibrutinib Maintenance Appears Safe in MCL Following Induction Therapy

June 25, 2019

Ibrutinib as a maintenance therapy for patients with mantle cell lymphoma who respond to frontline induction therapy with or without autologous stem cell transplant appeared safe and feasible, according to the results of a recent study presented at the 2019 ASCO Annual Meeting.

Dostarlimab Effective in Endometrial Cancer Regardless of MSI Status

May 28, 2019

Dostarlimab (TSR-042), an investigational anti–PD-1 therapy, demonstrated durable responses across subgroups of patients with microsatellite instability–high and microsatellite stable advanced or recurrent endometrial cancer, according to results from the phase I/II GARNET study.